Pediatric midline high-grade astrocytomas (mHGAs) are incurable with few treatment targets identified. Most tumors harbor mutations encoding p.Lys27Met in histone H3 variants.
In 40 treatment-naive mHGAs, 39 analyzed by whole-exome sequencing, we find additional somatic mutations specific to tumor location. Gain-of-function mutations in ACVR1 occur in tumors of the pons in conjunction with histone H3.1 p.Lys27Met substitution, whereas FGFR1 mutations or fusions occur in thalamic tumors associated with histone H3.3 p.Lys27Met substitution. Hyperactivation of the bone morphogenetic protein (BMP)-ACVR1 developmental pathway in mHGAs harboring ACVR1 mutations led to increased levels of phosphorylated SMAD1, SMAD5 and SMAD8 and upregulation of BMP downstream early-response genes in tumor cells. Global DNA methylation profiles were significantly associated with the p.Lys27Met alteration, regardless of the mutant histone H3 variant and irrespective of tumor location, supporting the role of this substitution in driving the epigenetic phenotype. This work considerably expands the number of potential treatment targets and further justifies pretreatment biopsy in pediatric mHGA as a means to orient therapeutic efforts in this disease.
We and others recently identified recurrent mutations in H3F3A, encoding histone 3 variant 3 (H3.3), in 38% of pediatric supratentorial HGAs and mutations affecting histone H3.3 or H3.1 in ~80% of brainstem HGAs (diffuse intrinsic pontine gliomas, DIPGs) [1] [2] [3] . Mutations affecting the histone H3 tail that change the glycine at position 34 to either arginine or valine (p.Gly34Arg or p.Gly34Val), as well as mutations in genes affecting histone H3 post-translational modifications at lysine 36, predominate in cortical tumors, whereas lysine-to-methionine substitutions at residue 27 (p.Lys27Met) occur in midline tumors 1,2,4,5 .
Herein we focus on the genomic (mutational spectrum and copy number alterations) and epigenetic (DNA methylation) landscape of treatment-naive pediatric midline (thalamus, cerebellum, spine and pons; non-cortical regions) high-grade astrocytomas (Figs. 1-3) . These tumors are often surgically challenging or inoperable, and published studies have mainly used material collected after therapy and have provided limited genomic data other than structural alterations and mutational analysis of histone H3 variant genes and TP53 (refs. 1,3,6,7) . We analyzed 40 mHGAs, with whole-exome sequencing data for 39 tumors, including 25 biopsies from DIPG cases (11 previously reported 2, 8 ; Online Methods and Supplementary Table 1) . The recurrent histone H3 gene mutation encoding p.Lys27Met was found in 37 of 40 cases (93%) and was distributed among three histone variant genes, including H3F3A (32/40 samples), HIST1H3B (4/39 samples) and HIST1H3C (1/39 samples). HIST1H3C also encodes the canonical histone H3.1 (as does HIST1H3B) and has not previously been reported to be mutated (Fig. 1) . All five histone H3.1 alterations occurred in the pons of younger cases (Supplementary Fig.  1 ). Histone H3.3 p.Lys27Met alterations occurred in multiple midline locations, including the brainstem (19/25) , thalamus (9/11) and rare locations for HGAs-the cerebellum, fourth ventricle and spinal cord (4/4). In contrast, only 1 histone H3.3 p.Lys27Met mutant was identified in 42 pediatric high-grade tumors located in cerebral hemispheres in a previously reported data set 2,5 ( Fig. 1 and Supplementary  Table 1) .
The pattern of somatic mutations in specific genes or gene pathways showed striking features ( Fig. 1 and Supplementary Fig. 1 ). Recurrent somatic mutations in the activin A receptor, type I gene (ACVR1) occurred in 5 of 39 mHGAs and overlapped with p.Lys27Met alterations Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma (5/5) , mainly in histone H3.1 (4/5) rather than histone H3.3 or wildtype histone H3 (P = 0.0003, Fisher's exact test; Supplementary Fig. 1 ). These specific amino acid residues in ACVR1 have previously been reported to be affected by germline mutations causing fibrodysplasia ossificans progressiva (FOP), an inherited musculoskeletal disease [9] [10] [11] [12] [13] [14] . The p.Arg206His, p.Gly328Glu and p.Gly356Asp substitutions result in ligand-independent activation of the kinase, leading to an increase in BMP signaling and increased phosphorylation of SMAD1, SMAD5 and SMAD8 (SMAD1/5/8) in tissues 10 , whereas the newly identified p.Gly328Val and p.Arg258Gly substitutions are predicted to exert gain-of-function effects similar to those for the previously described p.Arg258Ser, p.Gly328Glu, p.Gly328Trp and p.Gly328Arg alterations, on the basis of the physicochemical properties of the mutant residues and predicted protein structure ( Fig. 4 and Supplementary Table 2) 11, 12 . ACVR1, also known as ALK2, is a type I receptor of the mammalian transforming growth factor (TGF)-β signaling family with critical developmental roles in the mouse embryo 13 and in early left-right patterning 14 . Investigation of ACVR1 pathway activation using immunohistochemical staining for phosphorylated SMAD1/5/8 in DIPG samples showed positive staining only in tumors with mutant ACVR1 (4/4), including in DIPGs with the newly identified p.Gly328Val and p.Arg258Gly alterations (Fig. 2) .
In addition, in the primary cell line DIPGIV, which carries histone H3.1 p.Lys27Met and the new ACVR1 substitution p.Gly328Val, we demonstrated increased levels of phosphorylated SMAD1/5/8 compared to normal human astrocytes (NHA cells) and significantly increased expression of genes containing BMP response elements-ID1, ID2 and ID3-and SNAI1 compared to KNS42, a cell line with the histone H3.3 p.Gly34Val alteration and wild-type ACVR1 (Fig. 4) . These genes are early-response genes induced following active BMP2 signaling and represent SMAD1/5/8 downstream effectors 15, 16 .
We identified mutations in FGFR1 in association with histone H3.3 p.Lys27Met alteration in 4 of 39 cases: 3 thalamic HGAs also having NF1 mutations (previously reported in ref. 8 ) and 1 DIPG (Fig. 1) . These FGFR1 mutations affected hotspot residues in the tyrosine kinase domain of the FGFR1 receptor. They have been shown to lead to its constitutive activation in a subset of thalamic pilocytic astrocytomas, a grade I tumor that rarely progresses to higher-grade astrocytoma, and in NIH 3T3 cells 8 . Comparison with our data set of non-midline cortical HGA-HGG indicated that tumors carrying ACVR1 or FGFR1 mutations were exclusive to midline HGAs (P = 0.0040, Fisher's exact test; Fig. 1 and Supplementary Fig. 1b) .
TP53 mutations occurred in 28 of 40 samples, largely in combination with histone H3.3 p.Lys27Met alteration (25/28) as reported previously 1,2 and, to a much lesser extent, with histone H3.1 p.Lys27Met alteration (1/5) ( Fig. 1 and Supplementary Fig. 1b Figure 1 Genomic landscape of pediatric midline HGAs. Distribution of mutations and alterations in 40 pediatric midline high-grade astrocytomas (midline HGA) and 42 cortical high-grade astrocytomas and high-grade gliomas (cortical HGA-HGG) described in the study. Mutations (mut) were identified with whole-exome sequencing (WES) where available and are indicated by colored boxes. Amplifications (amp) and losses were identified using DNA methylation profile-derived copy number variant (methyl- Fig. 1 and Supplementary Tables 1 and 6 ). Three midline samples displayed no detectable mutation across H3F3A, HIST1H3B and HIST1H3C, even when sequenced at extremely high depth (average read depth across all tumors and genes of >20,000×; Supplementary Table 3) . These samples carried alterations described in adult HGA in the form of combined TP53 mutation, PDGFRA amplification and CDKN2A loss (mHGA35), PDGFRA and EGFR amplification and NF1 loss (mHGA36), or the previously identified FGFR1-TACC1 fusion 17,18 (mHGA37) ( Fig. 1 and Supplementary Tables 1, 3 and 4) . We identified somatic PDGFRA mutations in a small subset of pediatric mHGAs (5/39; Supplementary Table 1) . Notably, PDGFRA amplification occurred in 3 of 12 treatment-naive DIPGs ( Supplementary Fig. 2 and Supplementary Table 1) . Interestingly, a cerebellar HGA sample with multiple biopsies taken from different anatomical loci showed PDGFRA amplification in only one tumor site, whereas similar somatic mutation and DNA methylation profiles were observed across all tumor sites (Supplementary Fig. 3 ). This finding supports the view that PDGFRA amplifications precede therapy but can be further promoted by it, as described in radiation-induced supratentorial HGA 19 . Mutations in other growth factor receptor and component genes described to have focal gains or losses in DIPG 6, 7 or HGA (MET, RB1 and PARP1) showed low incidence in our data set ( Fig. 1 and Supplementary Tables 1 and 4-6) , whereas recurrent mutations in components of the phosphoinositide 3-kinase (PI3K) pathway, predicted to activate AKT signaling, were present in 10 of 39 mHGAs. With respect to alterations affecting telomere length, ATRX mutations were identified in nine midline tumors, exclusively in samples with histone H3.3 p.Lys27Met alteration and TP53 mutation, and affected older children 1 , whereas no TERT promoter mutations, assessed using targeted sequencing, were identified in mHGAs (Supplementary Table 1) .
Lysine-to-methionine substitutions in histone variants at residue Lys27 have recently been shown to inhibit SET domain-containing histone methyltransferases 20 , possibly accounting for the specific DNA methylation pattern we observed in non-brainstem tumors with the histone H3.3 p.Lys27Met alteration 4 . When clustering our samples by global DNA methylation, all samples with a given histone H3 alteration (absent or affecting Lys27 or Gly34) clustered together but did not group on the basis of tumor location within the brain, the particular histone H3 gene mutated, and additional partner mutations or structural alterations identified (Fig. 3 and Supplementary Figs. 4 and 5) . The global epigenetic profile is thus strongly associated with alteration of the histone H3 variant mark. Interestingly, TP53 alteration was associated with increased broad copy number changes as we previously showed 2 (average of 32 events per sample), indicating a level of genomic instability. The number of copy number changes was significantly higher in samples with the histone H3.3 p.Gly34Arg or p.Gly34Val alteration than in other groups (P = 0.02997; Supplementary Table 7) , in keeping with global hypomethylation identified in these tumors 4 .
The gain-of-function alterations in three growth factor receptor genes-ACVR1, FGFR1 and PDGFRA-associate with histone H3 p.Lys27Met variants in midline HGA. These mutations are not seen concurrently, and ACVR1 and FGFR1 mutations are mutually exclusive with TP53 alterations and privilege specific locations within the midline of the brain. ACVR1 mutations do not seem to correlate with differential survival in patients with HGA, although no definite conclusions can be drawn because of our limited sample size (Supplementary Fig. 6 ). The lack of reported central nervous system (CNS) tumor development in humans with FOP or Acvr1 (Alk2) mouse models suggests that aberrant activation of this pathway is not sufficient for tumorigenesis 10 and that it may act in concert with histone H3 p.Lys27Met substitution and other alterations we identified in the PI3K pathway to induce tumorigenesis (Fig. 1) . Interestingly, ACVR1 is mainly expressed at embryonic day (E) 14 in the cortex of mouse embryos and at very low levels in the brainstem, and aberrantly active ACVR1 leads to increased ventralization of zebrafish embryos 11, 12, 21 . Aberrant ACVR1 signaling in the brainstem, a midline structure, may specify a patterning defect in DIPG, as this gene is involved in left-right patterning development. FGFR signaling regulates neural progenitor maintenance and the development of the ventral midbrain 22 . Similar to ACVR1 mutations, the FGFR1 gainof-function mutations we identify only lead to grade I astrocytomas if present on their own in a tumor 8 npg l e t t e r s p.Gly34Val have been found in H3F3A and not in other histone genes thus far and invariably associate with TP53 and ATRX mutations in the cortex. In mHGA, mutations encoding p.Lys27Met arise in different histone H3 variants depending on age and tumor location. They associate with TP53 mutations or with activated neurodevelopmental growth factor receptor pathways through distinct hits in ACVR1, FGFR1 or PDGFRA to achieve tumorigenesis. These alterations in growth factor receptors and in members of the PI3K pathway offer previously unforeseen therapeutic possibilities in a deadly cancer, while the observed level of genomic instability calls for caution in the choice of adjuvant therapy whenever possible. Notably, we show that small-needle pretherapy biopsies can reliably identify the mutational landscape in HGA. This technique will allow for the tailoring of available therapies to the results obtained from stereotactic biopsy in children affected by this fatal brain tumor while effort continues to be made to target p.Lys27Met histone alterations. 
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